REN and hydrops fetalis: Sympathetic nervous, renin–angiotensin–aldosterone and cardiac natriuretic system implications are well-known and their inhibition is the cornerstone of chronic HF management, which has been recently implemented with sodium glucose co-transporter 2 modulators, even in HF-preserved ejection fractions (HFpEFs) up to 60% [1,2,3,4,5].